A prospective study on the role of CXCL13 in Lyme neuroborreliosis

Abstract

The definite diagnosis of acute Lyme neuroborreliosis (LNB) requires detection of an increased Borrelia burgdorferi–specific antibody index (AI). The B burgdorferi AI, however, is neg- ative in up to 20% of patients with early LNB and can remain elevated for years after adequate therapy; both of these factors can make the diagnosis difficult. Recent retrospective studies suggested the chemokine CXCL13 as a potential biomarker for LNB. To evaluate its diagnostic value, we conducted a prospective study.

Part of CIRS Nexus · Curated by Lauren Lowenstein, The Biotoxin Lady